Found vs Maximus: Biology-First Care or Low-Cost Semaglutide
Quick verdict: Found vs Maximus
Found emphasizes a biology-first, personalized medically supervised program with plans starting at $39 and broad insurance acceptance; Maximus is a lower flat direct-pay telemedicine option focused on compounded semaglutide at $132.99/month. Early verdict: choose Found for a holistic, insurance-friendly program and Maximus for a simple, low flat-rate compounded semaglutide option.
Explore Found plans starting at $39
How these programs differ at a glance
The comparison below focuses on the most distinctive differences between Found and Maximus: clinical approach and personalization, pricing and insurance handling, medication options and formulation, access model and telemedicine workflow, and geographic or availability notes. Both offer compounded medications, which are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Clinical approach and personalization
Found positions itself as a biology-first program that conducts a medical evaluation and builds a personalized program around metabolic biology, hormones, blood sugar regulation, sleep, and behavior. Maximus presents a straightforward GLP-1 telemedicine model focused on delivering compounded semaglutide prescribed by licensed doctors with no in-person visits. These are contrasting approaches: Found emphasizes holistic personalization; Maximus emphasizes simplicity and direct access to semaglutide.
Pricing and insurance handling
Found advertises getting started for as low as $39, notes most insurance is now accepted, and says Found handles insurance paperwork including a Medicare GLP-1 Bridge Program offering for eligible Part D members. Maximus lists a low flat rate at $132.99/month and operates on a direct-pay model that does not bill insurance. If insurance compatibility matters, Found explicitly accepts most insurance; if you want a predictable direct-pay price, Maximus lists $132.99/month.
Medication options and formulation
Found offers branded GLP-1s and compounded options including tirzepatide and semaglutide and states compounded GLP-1s are not FDA-approved and may not be available in all states. Found also notes certain medications are FDA-approved for conditions other than weight and disclaims affiliation with brand owners. Maximus focuses on compounded semaglutide through U.S.-based pharmacies and notes it fills prescriptions with the same active ingredient as branded GLP-1 products; Maximus also emphasizes that prescriptions are approved by licensed doctors and medication is compounded domestically. Both providers include compounded medication offerings and the same regulatory note about compounded drugs not being FDA-approved.
Access model and telemedicine workflow
Found combines medical evaluation, ongoing program features, and insurance handling as part of a medically supervised program. Maximus offers convenient telemedicine access with no clinic visits, prescriptions approved by licensed doctors, and shipments from trusted U.S. pharmacies. Maximus highlights no membership fees and transparent pricing; Found highlights a membership model with variable starting rates and insurance billing support. If you prefer no in-person visits and a single flat fee, Maximus is explicit about that model. If you prefer an insurance-handled, medically supervised membership with program elements beyond medication, Found is explicit about that approach.
Availability and program scale notes
Found claims insurance is accepted for many patients and references specific programs like Medicare GLP-1 Bridge Program for eligible Part D members. Maximus states its Weight Loss Protocol is available in all 50 states except Mississippi and notes a smaller public track record than larger competitors. Maximus also states that if a patient is not approved for treatment, medication costs will be fully refunded. Found emphasizes program claims about beginning to see results as soon as month 1 but does not supply guaranteed outcomes; both providers include the regulatory qualifier about compounded medications.
Comparison table: Found vs Maximus
| Criteria | Found | Maximus |
|---|---|---|
| Primary approach | Biology-first personalized medically supervised program | Direct-pay telemedicine focused on compounded semaglutide |
| Starting price | Get started for as low as $39 | $132.99 per month |
| Insurance handling | Most insurance now accepted; Found handles paperwork | No insurance billing; direct-pay only |
| Medications | Branded GLP-1s and compounded semaglutide, tirzepatide; availability varies | Compounded semaglutide filled through U.S. pharmacies |
| Telemedicine | Medically supervised program with evaluation and ongoing plan | Convenient online visits; no clinic visits required |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
See Maximus semaglutide pricing at $132.99/mo
What we know and what is not supplied
Both sources provide program descriptions, pricing starting points, and regulatory notes about compounded medications. Detailed clinical outcomes for each program, head-to-head efficacy comparisons, and comprehensive state-by-state availability for Found were not supplied in the source material and therefore are not included here.
Compare Found membership and insurance options
Bottom line: Choose Found vs Maximus
Found vs Maximus presents a clear tradeoff: Found is centered on a biology-first personalized, medically supervised program with plans starting at $39 and broad insurance acceptance; Maximus is a lower flat-rate, no-insurance telemedicine option offering compounded semaglutide at $132.99/month with prescriptions approved by licensed doctors and filled through U.S. pharmacies.
Choose Found if you want a holistic program built around metabolic biology, insurance handling, and personalized medical supervision.
Choose Maximus if you want a simple direct-pay semaglutide program at a low flat monthly rate with telemedicine access and U.S.-based pharmacy fulfillment.